{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-neuropathy","title":"PT-141 for Neuropathy: Evidence-Graded Review","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\n\n## Why PT-141 might help you\n\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \n\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\n\n## How these fit together\n\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\n\n## What the evidence actually shows\n\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no neuropathy cohorts (human tier, n>1000 across RECONNECT studies). Diabetic ED trials noted benefits in men with diabetes-related ED, yet measured sexual function scores only (human tier). No rat or animal studies directly test PT-141 on neuropathic pain models or nerve regeneration (preclinical tier: zero relevant studies located).\n\n## What scientists say\n\nResearchers describe PT-141 as a melanocortin agonist acting centrally on MC3/MC4 receptors to drive arousal independent of vascular pathways. Publications note its utility in PDE5 non-responders but explicitly limit claims to sexual dysfunction endpoints. No peer-reviewed statements link the compound to nerve repair or neuropathy resolution (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports center on erectile effects and libido. Users with presumed diabetic or age-related issues describe stronger spontaneous erections and mental arousal after 1–2 mg doses, sometimes combined with PDE5 inhibitors. Nausea and flushing are commonly noted side effects. No posts report changes in neuropathic pain, numbness, or nerve function (anecdotal tier). One thread contrasts PT-141 with Melanotan-2, noting the latter's limited animal data on nerve regeneration while stating PT-141 lacks such observations.\n\n## What people say on X\n\nNo matching posts discuss PT-141 in the context of neuropathy or neuropathic symptoms (anecdotal tier: zero relevant reports).\n\n## What we do not know\n\nHuman data on PT-141 for any neuropathy endpoint is absent. Preclinical work on melanocortin agonists and nerve injury is limited to unrelated compounds. Long-term effects on nerve health remain unstudied. Dose-response relationships for non-sexual outcomes are unknown.\n\n## Safety and limits\n\nCommon effects in human trials include nausea (up to 40% of participants), flushing, and headache. Serious adverse events were rare in HSDD studies. PT-141 is not approved or studied for neuropathy; any use falls outside labeled indications. Evidence grade remains mechanistic or anecdotal for this condition.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials examine PT-141 for neuropathy itself.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the queried condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early MT-II study included men with peripheral neuropathic injury but measured only erectile response.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Shows incidental inclusion of neuropathy patients without neuropathy outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 bremelanotide trials demonstrated increased desire scores versus placebo in HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides human efficacy data but not for neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report stronger erections and arousal but no changes in neuropathic pain or nerve function.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents user experience separate from clinical data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://wjmh.org/DOIx.php?id=10.5534/wjmh.200007","title":"Novel Emerging Therapies for Erectile Dysfunction","quote":"Bremelanotide is a carboxylated metabolite of MT-II, and was formerly known as PT-141.","summary":"Reviews PT-141 studies limited to ED endpoints; no neuropathy data.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"47223ca5edb11d9aeaa822121caa428c9337418f0c77f8b74196368ab8e80523"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18206919/","title":"Salvage of sildenafil failures with bremelanotide","quote":"Organic risk factors for ED that were present in the 10 subjects included ... peripheral neuropathic injury ...","summary":"Small crossover study of related compound including neuropathy patients but only ED outcomes.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"unverified","prev":"47223ca5edb11d9aeaa822121caa428c9337418f0c77f8b74196368ab8e80523","hash":"8b78d7eb02167b83122c9cc2effc05fd2f5100d0f3b8bfb3bda5be76eef39abb"},{"id":"s3","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder.","summary":"Phase 3 HSDD data; no neuropathy cohorts.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"verified","prev":"8b78d7eb02167b83122c9cc2effc05fd2f5100d0f3b8bfb3bda5be76eef39abb","hash":"659ba8098942df67c20d8a368ed5f5c2a7fa926fc9899544d09157a970fc14b9"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1clpo4k/taken_pt141_twice_now_and_i_am_happily_amazed/","title":"Taken PT-141 twice now and I am happily amazed","quote":"This stuff works for me!!! Not only did I feel 19 again and gave me the best hard-ons I've ever had...","summary":"User reports focus on sexual effects; no neuropathy mentions.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"unverified","prev":"659ba8098942df67c20d8a368ed5f5c2a7fa926fc9899544d09157a970fc14b9","hash":"edfce5464843768c4c91d049cb988df949c2f5d41ff6e4403bf666ddec5f908b"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:13:09.236Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Neuropathy: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\n\n## Why PT-141 might help you\n\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \n\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\n\n## How these fit together\n\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\n\n## What the evidence actually shows\n\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no neuropathy cohorts (human tier, n>1000 across RECONNECT studies). Diabetic ED trials noted benefits in men with diabetes-related ED, yet measured sexual function scores only (human tier). No rat or animal studies directly test PT-141 on neuropathic pain models or nerve regeneration (preclinical tier: zero relevant studies located).\n\n## What scientists say\n\nResearchers describe PT-141 as a melanocortin agonist acting centrally on MC3/MC4 receptors to drive arousal independent of vascular pathways. Publications note its utility in PDE5 non-responders but explicitly limit claims to sexual dysfunction endpoints. No peer-reviewed statements link the compound to nerve repair or neuropathy resolution (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports center on erectile effects and libido. Users with presumed diabetic or age-related issues describe stronger spontaneous erections and mental arousal after 1–2 mg doses, sometimes combined with PDE5 inhibitors. Nausea and flushing are commonly noted side effects. No posts report changes in neuropathic pain, numbness, or nerve function (anecdotal tier). One thread contrasts PT-141 with Melanotan-2, noting the latter's limited animal data on nerve regeneration while stating PT-141 lacks such observations.\n\n## What people say on X\n\nNo matching posts discuss PT-141 in the context of neuropathy or neuropathic symptoms (anecdotal tier: zero relevant reports).\n\n## What we do not know\n\nHuman data on PT-141 for any neuropathy endpoint is absent. Preclinical work on melanocortin agonists and nerve injury is limited to unrelated compounds. Long-term effects on nerve health remain unstudied. Dose-response relationships for non-sexual outcomes are unknown.\n\n## Safety and limits\n\nCommon effects in human trials include nausea (up to 40% of participants), flushing, and headache. Serious adverse events were rare in HSDD studies. PT-141 is not approved or studied for neuropathy; any use falls outside labeled indications. Evidence grade remains mechanistic or anecdotal for this condition.","claims":[{"id":"c1","text":"No human trials examine PT-141 for neuropathy itself.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the queried condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early MT-II study included men with peripheral neuropathic injury but measured only erectile response.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Shows incidental inclusion of neuropathy patients without neuropathy outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 bremelanotide trials demonstrated increased desire scores versus placebo in HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides human efficacy data but not for neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report stronger erections and arousal but no changes in neuropathic pain or nerve function.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents user experience separate from clinical data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://wjmh.org/DOIx.php?id=10.5534/wjmh.200007","title":"Novel Emerging Therapies for Erectile Dysfunction","quote":"Bremelanotide is a carboxylated metabolite of MT-II, and was formerly known as PT-141.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18206919/","title":"Salvage of sildenafil failures with bremelanotide","quote":"Organic risk factors for ED that were present in the 10 subjects included ... peripheral neuropathic injury ...","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1clpo4k/taken_pt141_twice_now_and_i_am_happily_amazed/","title":"Taken PT-141 twice now and I am happily amazed","quote":"This stuff works for me!!! Not only did I feel 19 again and gave me the best hard-ons I've ever had...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":30634,"tokens_out":2919,"cost":0.04559,"prev_hash":"genesis","hash":"3aca6ffc08a4edf61a9270012c48c7c141a783aa1a54013a0bee5881fc96eef3"}],"provenance":[{"ts":"2026-06-30T01:13:09.236Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Neuropathy\nSlug: pt-141-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from pep","response":"{\n  \"slug\": \"pt-141-neuropathy\",\n  \"title\": \"PT-141 for Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\\n\\n## Why PT-141 might help you\\n\\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \\n\\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \\n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\\n\\n## How these fit together\\n\\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\\n\\n## What the evidence actually shows\\n\\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no n","tokens_in":30634,"tokens_out":2919,"cost":0,"prev":"genesis","hash":"9f7572b6c88115094f42e33f56806e19f07b41b13338368809a8daa3ae848528"},{"ts":"2026-07-17T02:41:08.368Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-neuropathy","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9f7572b6c88115094f42e33f56806e19f07b41b13338368809a8daa3ae848528","hash":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"}],"energy":{"passes":2,"tokens_in":30634,"tokens_out":2919,"tokens_total":33553,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"},"posted_at":"2026-06-29T21:32:54.259Z","created_at":"2026-06-29T21:32:54.259Z","updated_at":"2026-07-17T02:41:08.368Z","machine":{"shape":"article.machine/v1","slug":"pt-141-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-neuropathy","json":"https://miscsubjects.com/api/articles/pt-141-neuropathy","bundle":"https://miscsubjects.com/api/articles/pt-141-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-neuropathy","json":"/api/articles/pt-141-neuropathy","markdown":"/api/articles/pt-141-neuropathy/bundle?format=markdown","skill":"/api/articles/pt-141-neuropathy/skill","topology":"/api/articles/pt-141-neuropathy/topology","versions":"/api/articles/pt-141-neuropathy/revisions","invocations":"/api/articles/pt-141-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"b9880ee2585de9f330947f4ba8986039ec2811c9a1bfb2ec531bb143f3b4627a","object":{"object_type":"article-object","identity":{"id":"article:pt-141-neuropathy","slug":"pt-141-neuropathy","title":"PT-141 for Neuropathy: Evidence-Graded Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-neuropathy\ndescription: Apply the PT-141 for Neuropathy: Evidence-Graded Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 for Neuropathy: Evidence-Graded Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-neuropathy.\n- Read claims and relationships at /api/articles/pt-141-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Neuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerv\n\n## Representations\n\n- Human: /a/pt-141-neuropathy\n- JSON: /api/articles/pt-141-neuropathy\n- Relationships: /api/articles/pt-141-neuropathy/topology\n- History: /api/articles/pt-141-neuropathy/revisions\n"},"json":{"route":"/api/articles/pt-141-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","pt","141","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-neuropathy/invocations?status=success","failure_events":"/api/articles/pt-141-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-neuropathy","title":"PT-141 for Neuropathy: Evidence-Graded Review","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\n\n## Why PT-141 might help you\n\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \n\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\n\n## How these fit together\n\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\n\n## What the evidence actually shows\n\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no neuropathy cohorts (human tier, n>1000 across RECONNECT studies). Diabetic ED trials noted benefits in men with diabetes-related ED, yet measured sexual function scores only (human tier). No rat or animal studies directly test PT-141 on neuropathic pain models or nerve regeneration (preclinical tier: zero relevant studies located).\n\n## What scientists say\n\nResearchers describe PT-141 as a melanocortin agonist acting centrally on MC3/MC4 receptors to drive arousal independent of vascular pathways. Publications note its utility in PDE5 non-responders but explicitly limit claims to sexual dysfunction endpoints. No peer-reviewed statements link the compound to nerve repair or neuropathy resolution (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports center on erectile effects and libido. Users with presumed diabetic or age-related issues describe stronger spontaneous erections and mental arousal after 1–2 mg doses, sometimes combined with PDE5 inhibitors. Nausea and flushing are commonly noted side effects. No posts report changes in neuropathic pain, numbness, or nerve function (anecdotal tier). One thread contrasts PT-141 with Melanotan-2, noting the latter's limited animal data on nerve regeneration while stating PT-141 lacks such observations.\n\n## What people say on X\n\nNo matching posts discuss PT-141 in the context of neuropathy or neuropathic symptoms (anecdotal tier: zero relevant reports).\n\n## What we do not know\n\nHuman data on PT-141 for any neuropathy endpoint is absent. Preclinical work on melanocortin agonists and nerve injury is limited to unrelated compounds. Long-term effects on nerve health remain unstudied. Dose-response relationships for non-sexual outcomes are unknown.\n\n## Safety and limits\n\nCommon effects in human trials include nausea (up to 40% of participants), flushing, and headache. Serious adverse events were rare in HSDD studies. PT-141 is not approved or studied for neuropathy; any use falls outside labeled indications. Evidence grade remains mechanistic or anecdotal for this condition.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials examine PT-141 for neuropathy itself.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the queried condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early MT-II study included men with peripheral neuropathic injury but measured only erectile response.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Shows incidental inclusion of neuropathy patients without neuropathy outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 bremelanotide trials demonstrated increased desire scores versus placebo in HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides human efficacy data but not for neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report stronger erections and arousal but no changes in neuropathic pain or nerve function.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents user experience separate from clinical data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://wjmh.org/DOIx.php?id=10.5534/wjmh.200007","title":"Novel Emerging Therapies for Erectile Dysfunction","quote":"Bremelanotide is a carboxylated metabolite of MT-II, and was formerly known as PT-141.","summary":"Reviews PT-141 studies limited to ED endpoints; no neuropathy data.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"47223ca5edb11d9aeaa822121caa428c9337418f0c77f8b74196368ab8e80523"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18206919/","title":"Salvage of sildenafil failures with bremelanotide","quote":"Organic risk factors for ED that were present in the 10 subjects included ... peripheral neuropathic injury ...","summary":"Small crossover study of related compound including neuropathy patients but only ED outcomes.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"unverified","prev":"47223ca5edb11d9aeaa822121caa428c9337418f0c77f8b74196368ab8e80523","hash":"8b78d7eb02167b83122c9cc2effc05fd2f5100d0f3b8bfb3bda5be76eef39abb"},{"id":"s3","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder.","summary":"Phase 3 HSDD data; no neuropathy cohorts.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"verified","prev":"8b78d7eb02167b83122c9cc2effc05fd2f5100d0f3b8bfb3bda5be76eef39abb","hash":"659ba8098942df67c20d8a368ed5f5c2a7fa926fc9899544d09157a970fc14b9"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1clpo4k/taken_pt141_twice_now_and_i_am_happily_amazed/","title":"Taken PT-141 twice now and I am happily amazed","quote":"This stuff works for me!!! Not only did I feel 19 again and gave me the best hard-ons I've ever had...","summary":"User reports focus on sexual effects; no neuropathy mentions.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:13:06.791Z","link_status":"ok","quote_status":"unverified","prev":"659ba8098942df67c20d8a368ed5f5c2a7fa926fc9899544d09157a970fc14b9","hash":"edfce5464843768c4c91d049cb988df949c2f5d41ff6e4403bf666ddec5f908b"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:13:09.236Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Neuropathy: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\n\n## Why PT-141 might help you\n\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \n\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\n\n## How these fit together\n\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\n\n## What the evidence actually shows\n\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no neuropathy cohorts (human tier, n>1000 across RECONNECT studies). Diabetic ED trials noted benefits in men with diabetes-related ED, yet measured sexual function scores only (human tier). No rat or animal studies directly test PT-141 on neuropathic pain models or nerve regeneration (preclinical tier: zero relevant studies located).\n\n## What scientists say\n\nResearchers describe PT-141 as a melanocortin agonist acting centrally on MC3/MC4 receptors to drive arousal independent of vascular pathways. Publications note its utility in PDE5 non-responders but explicitly limit claims to sexual dysfunction endpoints. No peer-reviewed statements link the compound to nerve repair or neuropathy resolution (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports center on erectile effects and libido. Users with presumed diabetic or age-related issues describe stronger spontaneous erections and mental arousal after 1–2 mg doses, sometimes combined with PDE5 inhibitors. Nausea and flushing are commonly noted side effects. No posts report changes in neuropathic pain, numbness, or nerve function (anecdotal tier). One thread contrasts PT-141 with Melanotan-2, noting the latter's limited animal data on nerve regeneration while stating PT-141 lacks such observations.\n\n## What people say on X\n\nNo matching posts discuss PT-141 in the context of neuropathy or neuropathic symptoms (anecdotal tier: zero relevant reports).\n\n## What we do not know\n\nHuman data on PT-141 for any neuropathy endpoint is absent. Preclinical work on melanocortin agonists and nerve injury is limited to unrelated compounds. Long-term effects on nerve health remain unstudied. Dose-response relationships for non-sexual outcomes are unknown.\n\n## Safety and limits\n\nCommon effects in human trials include nausea (up to 40% of participants), flushing, and headache. Serious adverse events were rare in HSDD studies. PT-141 is not approved or studied for neuropathy; any use falls outside labeled indications. Evidence grade remains mechanistic or anecdotal for this condition.","claims":[{"id":"c1","text":"No human trials examine PT-141 for neuropathy itself.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the queried condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early MT-II study included men with peripheral neuropathic injury but measured only erectile response.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Shows incidental inclusion of neuropathy patients without neuropathy outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 bremelanotide trials demonstrated increased desire scores versus placebo in HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides human efficacy data but not for neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report stronger erections and arousal but no changes in neuropathic pain or nerve function.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents user experience separate from clinical data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:13:08.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://wjmh.org/DOIx.php?id=10.5534/wjmh.200007","title":"Novel Emerging Therapies for Erectile Dysfunction","quote":"Bremelanotide is a carboxylated metabolite of MT-II, and was formerly known as PT-141.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18206919/","title":"Salvage of sildenafil failures with bremelanotide","quote":"Organic risk factors for ED that were present in the 10 subjects included ... peripheral neuropathic injury ...","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1clpo4k/taken_pt141_twice_now_and_i_am_happily_amazed/","title":"Taken PT-141 twice now and I am happily amazed","quote":"This stuff works for me!!! Not only did I feel 19 again and gave me the best hard-ons I've ever had...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":30634,"tokens_out":2919,"cost":0.04559,"prev_hash":"genesis","hash":"3aca6ffc08a4edf61a9270012c48c7c141a783aa1a54013a0bee5881fc96eef3"}],"provenance":[{"ts":"2026-06-30T01:13:09.236Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Neuropathy\nSlug: pt-141-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from pep","response":"{\n  \"slug\": \"pt-141-neuropathy\",\n  \"title\": \"PT-141 for Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\\n\\n## Why PT-141 might help you\\n\\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \\n\\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \\n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\\n\\n## How these fit together\\n\\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\\n\\n## What the evidence actually shows\\n\\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no n","tokens_in":30634,"tokens_out":2919,"cost":0,"prev":"genesis","hash":"9f7572b6c88115094f42e33f56806e19f07b41b13338368809a8daa3ae848528"},{"ts":"2026-07-17T02:41:08.368Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-neuropathy","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9f7572b6c88115094f42e33f56806e19f07b41b13338368809a8daa3ae848528","hash":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"}],"energy":{"passes":2,"tokens_in":30634,"tokens_out":2919,"tokens_total":33553,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"},"posted_at":"2026-06-29T21:32:54.259Z","created_at":"2026-06-29T21:32:54.259Z","updated_at":"2026-07-17T02:41:08.368Z","machine":{"shape":"article.machine/v1","slug":"pt-141-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-neuropathy","json":"https://miscsubjects.com/api/articles/pt-141-neuropathy","bundle":"https://miscsubjects.com/api/articles/pt-141-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-neuropathy","json":"/api/articles/pt-141-neuropathy","markdown":"/api/articles/pt-141-neuropathy/bundle?format=markdown","skill":"/api/articles/pt-141-neuropathy/skill","topology":"/api/articles/pt-141-neuropathy/topology","versions":"/api/articles/pt-141-neuropathy/revisions","invocations":"/api/articles/pt-141-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"b9880ee2585de9f330947f4ba8986039ec2811c9a1bfb2ec531bb143f3b4627a"}}}